Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

JICA Supports Takeda’s Access to Medicines Strategy

By Drug Discovery Trends Editor | September 12, 2016

Takeda announced that its operational plan to improve Access to Medicines in Kenya will be supported by the Japan International Cooperation Agency (JICA), as part of JICA’s Public-Private-Partnership program named the Preparatory Survey for the Base of the Economic Pyramid.

“We are delighted to receive support from JICA for our efforts in Access to Medicines and to enter into this Public-Private Partnership,” said Isabel Torres, Global Head, Access to Medicine. “A combination of factors, including, insufficient medical facilities, inadequate infrastructure, low-levels of effective transportation, makes improvements in Access to Medicines in the sub-Saharan Africa region, a matter of urgency. Takeda aims to make a contribution to address barriers to access via multiple partnerships, including this one with JICA.”

The purpose of this Public-Private-Partnership program is to study income levels of patients with Non-Communicable Diseases (NCDs) in the sub-Saharan Africa region, a pioneering activity to understand how to improve access to medicines and healthcare for patients, by determining their affordability levels. The study, which commences in October 2016 and is expected to conclude in March 2017, will be implemented primarily via Takeda’s recently opened Nairobi office. Primarily, Takeda aims to optimize the program to provide our innovative medicines to those patients in need by performing a field study on income levels of patients with NCDs in Kenya, and understanding the burden of related medical expenses.

As part of its Access to Medicines strategy, Takeda also recently announced the signing of agreements with The University of Nairobi, The Elewa Cancer Foundation and Pan African Heart Foundation (PANAHF) to address a range of access barriers to address significant disease burdens in sub-Saharan to help address the significant unmet medical needs of patients across the region (see pages 2 & 3 for further details).

In regions such as sub-Saharan Africa, the ratio of diagnosis and treatment for NCDs is extremely low.1,2 Regardless of whether these diseases are treatable, many patients lose their lives due to insufficient treatment due to multiple access barriers.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50